Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Interv Cardiol ; 17: e12, 2022 Jan.
Article in English | MEDLINE | ID: mdl-37600899

ABSTRACT

Calcified disease increases procedural challenges and is associated with worse outcomes in percutaneous coronary intervention. Coronary intravascular lithotripsy is a new balloon-based modality for treating calcified disease with deep circumferential calcification. Its main benefit is simplicity and safety compared to atherectomy. However, atherectomy remains the modality of choice in balloon-uncrossable lesions. More than one modality is often needed for treatment of calcified disease. The authors present a case of a balloon-uncrossable calcified ostial left circumflex lesion which was first treated with rotational atherectomy. However, there was haematoma formation in the ostial circumflex extending into left main coronary artery, together with suboptimal preparation of calcified disease. Intravascular coronary lithotripsy was then used to successfully prepare the calcified lesion for stenting without causing extension of the haematoma.

2.
Catheter Cardiovasc Interv ; 97(2): E194-E197, 2021 02 01.
Article in English | MEDLINE | ID: mdl-32367683

ABSTRACT

OBJECTIVE: To determine whether COVID-19 may adversely affect outcome of myocardial infarction (MI) patients in Hong Kong, China. BACKGROUND: The COVID-19 pandemic has infected thousands of people and placed enormous stress on healthcare system. Apart from being an infectious disease, it may affect human behavior and healthcare resource allocation which potentially cause treatment delay in MI. METHODS: This was a single center cross-sectional observational study. From November 1, 2019 to March 31, 2020, we compared outcome of patients admitted for acute ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) before (group 1) and after (group 2) January 25, 2020 which was the date when Hong Kong hospitals launched emergency response measures to combat COVID-19. RESULTS: There was a reduction in daily emergency room attendance since January 25, 2020 (group 1,327/day vs. group 2,231/day) and 149 patients with diagnosis of MI were included into analysis (group 1 N = 85 vs. group 2 N = 64). For STEMI, patients in group 2 tended to have longer symptom-to-first medical contact time and more presented out of revascularization window (group 1 27.8 vs. group 2 33%). The primary composite outcome of in-hospital death, cardiogenic shock, sustained ventricular tachycardia or fibrillation (VT/VF) and use of mechanical circulatory support (MCS) was significantly worse in group 2 (14.1 vs. 29.7%, p = .02). CONCLUSIONS: More MI patients during COVID-19 outbreak had complicated in-hospital course and worse outcomes. Besides direct infectious complications, cardiology community has to acknowledge the indirect effect of communicable disease on our patients and system of care.


Subject(s)
COVID-19/epidemiology , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Aged , Aged, 80 and over , COVID-19/therapy , Cross-Sectional Studies , Female , Hong Kong , Hospital Mortality , Hospitalization , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Time-to-Treatment , Treatment Outcome
4.
EuroIntervention ; 14(7): 780-788, 2018 Sep 20.
Article in English | MEDLINE | ID: mdl-29901444

ABSTRACT

AIMS: This study aimed to establish the early healing and neointimal transformation profile of the new polymer-free BioFreedom stent through sequential optical coherence tomography (OCT) within the first nine months following stent implantation. METHODS AND RESULTS: We randomly assigned 104 BFS recipients to one of five groups with angiography and OCT follow-up at 1, 2, 3, 4, or 5 months, together with another follow-up for all at nine months. The primary endpoint was the degree of OCT-detected strut coverage at nine months. From 1, 2, 3, 4, and 5 months, median neointimal strut coverage increased from 85.8, 87.0, 88.6, 96.8 to 97.1%, respectively, to 99.6% (IQR 98.2-99.9) at nine months. At nine months, median percent neointimal volume was 13.0% and angiographic late lumen loss was 0.21±0.30 mm. Major adverse cardiac events (MACE) were limited to one non-cardiac death, one non-ST-elevation myocardial infarction not related to BFS, and two target lesion revascularisations without stent thrombosis (MACE rate 4.0%). CONCLUSIONS: Neointimal strut coverage of the BFS was rapid and the BFS was shown to be clinically safe and effective.


Subject(s)
Coronary Artery Disease , Coronary Restenosis , Drug-Eluting Stents , Percutaneous Coronary Intervention , Coronary Angiography , Humans , Polymers , Prospective Studies , Prosthesis Design , Sirolimus/analogs & derivatives , Tomography, Optical Coherence , Treatment Outcome
5.
Circ Cardiovasc Interv ; 11(4): e006034, 2018 04.
Article in English | MEDLINE | ID: mdl-29654119

ABSTRACT

BACKGROUND: Durable polymers used in drug-eluting stents are considered a potential cause of hypersensitivity inflammatory response adversely affecting stent healing. Using a sequential follow-up with optical coherence tomography, we compared the differences in healing profiles of 2 drug-eluting stents with a biodegradable or durable polymer. METHODS AND RESULTS: Sixty patients with multivessel disease were prospectively enrolled to receive both study stents, which were randomly assigned to 2 individual vessels, a Resolute Integrity zotarolimus-eluting stent with a durable BioLinx polymer and a BioMatrix NeoFlex Biolimus A9-eluting stent with a biodegradable polylactic acid polymer. Optical coherence tomography was performed at baseline, then in 5 randomly assigned monthly groups at 2 to 6 months, and at 9 months in all patients. The primary end point was the difference in optical coherence tomography strut coverage at 9 months. Key secondary end points included angiographic late lumen loss and composite major adverse cardiac events (cardiac death, myocardial infarction, target lesion revascularization, and definite or probable stent thrombosis) at 9 months. Resolute Integrity zotarolimus-eluting stent showed significantly better strut coverage than BioMatrix NeoFlex Biolimus A9-eluting stent at 2 to 6 months (P<0.001) and less variance of percent coverage at 9 months, 99.7% (interquartile range, 99.1-100) versus 99.6% (interquartile range, 96.8-99.9; difference, 0.10; 95% confidence interval, 0.00-1.05; P<0.001). No significant difference was observed in major adverse cardiac events or angiographic end points. CONCLUSIONS: Despite having a durable polymer, Resolute Integrity zotarolimus-eluting stent exhibited better strut coverage than BioMatrix NeoFlex Biolimus A9-eluting stent having a biodegradable polymer; both showed similar antiproliferative efficacy. This novel, longitudinal, sequential optical coherence tomography protocol using each patient as own control could achieve conclusive results in small sample size. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01742507.


Subject(s)
Absorbable Implants , Cardiovascular Agents/administration & dosage , Coronary Artery Disease/surgery , Coronary Restenosis/diagnostic imaging , Coronary Vessels/surgery , Drug-Eluting Stents , Neointima , Percutaneous Coronary Intervention/instrumentation , Sirolimus/analogs & derivatives , Tomography, Optical Coherence , Aged , Cardiovascular Agents/adverse effects , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Restenosis/etiology , Coronary Vessels/diagnostic imaging , Female , Hong Kong , Humans , Male , Middle Aged , Percutaneous Coronary Intervention/adverse effects , Predictive Value of Tests , Prospective Studies , Prosthesis Design , Sirolimus/administration & dosage , Sirolimus/adverse effects , Time Factors , Treatment Outcome
6.
J Int Med Res ; 46(1): 457-463, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28758853

ABSTRACT

Objective To evaluate the 1-year clinical outcomes of patients who received the Resolute Onyx™ stent. Methods This was a single-centre, retrospective registry analysis that reviewed the clinical data from all patients who were implanted with a Resolute Onyx™ stent between March 2015 and February 2016. Clinical follow-up was performed at 1 year post-implantation. Results A total of 252 patients received a Resolute Onyx™ stent and two patients were lost to follow-up. The mean age of the cohort was 66.9 years and 113 (45.2%) had diabetes mellitus. Thirty-eight patients (15.2%) had left main disease and 73 (29.2%) had three-vessel disease. A total of 175 patients (70.0%) had small vessel disease (<2.75 mm) and 210 (84.0%) had long lesions (>20 mm). The 1-year target lesion failure was 4.4% (11 of 250), cardiovascular death occurred in eight patients (3.2%), ischaemia-driven target lesion revascularization was undertaken in five patients (2.0%) and stent thrombosis occurred in one patient (0.4%). Conclusion The Resolute Onyx™ stent showed a favourable 1-year clinical performance in a real-world population.


Subject(s)
Coronary Artery Disease/drug therapy , Coronary Thrombosis/drug therapy , Diabetes Mellitus/drug therapy , Immunosuppressive Agents/therapeutic use , Myocardial Infarction/drug therapy , Registries , Sirolimus/analogs & derivatives , Aged , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Coronary Artery Disease/surgery , Coronary Thrombosis/diagnostic imaging , Coronary Thrombosis/mortality , Coronary Thrombosis/surgery , Diabetes Mellitus/diagnostic imaging , Diabetes Mellitus/mortality , Diabetes Mellitus/surgery , Drug-Eluting Stents , Female , Humans , Immunosuppressive Agents/pharmacokinetics , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/mortality , Myocardial Infarction/surgery , Percutaneous Coronary Intervention , Retrospective Studies , Sirolimus/pharmacokinetics , Sirolimus/therapeutic use , Survival Analysis , Time Factors , Treatment Outcome
7.
J Int Med Res ; 45(1): 134-146, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28222641

ABSTRACT

Objective The CYP2C19 loss-of-function (LoF) allele is present in half of the East Asian population and is associated with high on-treatment platelet reactivity (HTPR). This study aimed to investigate whether a rapid genotyping-guided approach is feasible and efficacious for selecting P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome (ACS). Methods This was a single-centre, prospective, randomized, open-label study. A total of 132 patients with ACS were randomized to the rapid genotyping-guided treatment group (GG, N = 65) or the standard treatment group (SG, N = 67). Patients in the GG group were genotyped by the Verigene system. Patients with the CYP2C19 LoF allele were switched to ticagrelor and all remaining patients continued on clopidogrel. The endpoints were HTPR at 24 hours after the first loading dose of clopidogrel and 1 month afterwards. Results Forty patients in the GG group switched to ticagrelor, while others continued on clopidogrel. The incidence of HTPR in the GG vs SG groups was 9.2% vs 40.3% at 24 hours and 6.5% vs 32.3% at 1 month, respectively. Rapid point-of-care genotyping showed 100% concordance with conventional genotyping by real-time polymerase chain reaction. Conclusions In Chinese patients suffering from ACS, the rapid genotyping-guided approach for selecting P2Y12 receptor blockers is feasible and reduces the incidence of HTPR. Clinical Trial Registration URL: http://clinicaltrials.gov . Unique identifier: NCT01994941.


Subject(s)
Acute Coronary Syndrome/drug therapy , Adenosine/analogs & derivatives , Cytochrome P-450 CYP2C19/genetics , Receptors, Purinergic P2Y12/genetics , Thrombosis/prevention & control , Ticlopidine/analogs & derivatives , Acute Coronary Syndrome/blood , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/genetics , Adenosine/therapeutic use , Aged , Alleles , Asian People , Blood Platelets/drug effects , Blood Platelets/metabolism , Blood Platelets/pathology , Clopidogrel , Cytochrome P-450 CYP2C19/deficiency , Female , Gene Expression , Gene Frequency , Genotype , Genotyping Techniques , Humans , Male , Middle Aged , Mutation , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/therapeutic use , Prospective Studies , Purinergic P2Y Receptor Antagonists/therapeutic use , Receptors, Purinergic P2Y12/metabolism , Thrombosis/diagnosis , Thrombosis/genetics , Thrombosis/metabolism , Ticagrelor , Ticlopidine/therapeutic use
8.
Article in English | MEDLINE | ID: mdl-27418609

ABSTRACT

BACKGROUND: Current monotherapy drug-eluting stents are associated with impaired healing, neoatherosclerosis, and late stent thrombosis. The healing profile and neointimal transformation of the first dual-therapy endothelial progenitor cell-capturing sirolimus-eluting stent are unknown. METHODS AND RESULTS: In this prospective, single-center study, 61 patients treated with the Combo stent had optical coherence tomography at baseline, early follow-up (4 monthly groups in a 1:2:2:1 ratio from 2 to 5 months), 9 months, and 24 months. Optical coherence tomography early strut coverage increased from 77.1% to 92.5% to 92.7% to 94.9% between 2 and 5 months. At 9 months, the major adverse cardiac event rate was 1.64%, and angiographic in-stent late loss was 0.24 mm (0.08-0.40). The 36-month major adverse cardiac event rate was 3.3%. From 9 to 24 months, neointimal regression was confirmed by optical coherence tomography: neointimal thickness (median [first quartile and third quartile]), 0.14 mm (0.08 and 0.21) versus 0.12 mm (0.07 and 0.19), P<0.001; neointimal volume, 29.9 mm(3) (22.1 and 43.2) versus 26.2 mm(3) (19.6 and 35.8), P=0.003; and percent neointimal volume, 17.8% (12.2 and 21.2) versus 15.7% (11.2 and 19.4), P=0.01. No definite or probable late stent thrombosis was recorded. CONCLUSIONS: With additional endothelial progenitor cell-capturing technology, the Combo stent exhibits a unique late neointimal regression (from 9 to 24 months) that has not been reported in any drug-eluting stents, translating into good 36-month clinical results with minimal restenosis and no late stent thrombosis. This is the first study testing the concept of using a longitudinal sequential optical coherence tomography protocol to continuously document early healing profile and late neointimal transformation, predicting long-term outcomes of a new novel stent platform. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT01274234, NCT01756807, and NCT02263313.


Subject(s)
Cardiovascular Agents/administration & dosage , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/therapy , Coronary Vessels/drug effects , Coronary Vessels/diagnostic imaging , Drug-Eluting Stents , Endothelial Progenitor Cells/transplantation , Neointima , Percutaneous Coronary Intervention/instrumentation , Sirolimus/administration & dosage , Tomography, Optical Coherence , Aged , Cardiovascular Agents/adverse effects , Combined Modality Therapy , Coronary Angiography , Coronary Restenosis/diagnostic imaging , Coronary Restenosis/etiology , Female , Humans , Male , Middle Aged , Percutaneous Coronary Intervention/adverse effects , Predictive Value of Tests , Prospective Studies , Prosthesis Design , Risk Factors , Sirolimus/adverse effects , Time Factors , Treatment Outcome , Wound Healing
SELECTION OF CITATIONS
SEARCH DETAIL
...